LANSING, Mich. – A significant boost is coming to the Lansing region as IONETIX Corporation announces a substantial investment of $25,750,000, expected to create 53 new jobs. Specializing in radiopharmaceuticals and targeted alpha therapy agents, IONETIX is set to enhance its role in diagnostic imaging and cancer treatment.
Governor Gretchen Whitmer highlighted the impact of this investment, stating, “Today’s $25 million investment in Lansing will create 53 good-paying jobs and build on Michigan’s leadership in the biotech and life sciences industries. IONETIX Corporation is betting on Michigan and doubling down on their established presence in Lansing.” She emphasized the collaborative environment in Michigan that aids business growth and job creation.
Matt McCauley, Senior Vice President for Regional Development at the MEDC, expressed enthusiasm about the company’s decision, noting that “Team Michigan welcomes IONETIX Corporation’s expansion, furthering Michigan’s leadership in the life sciences and medical technology industries. We applaud the company’s vision to Make it in Michigan.”
The investment will focus on renovating and expanding the company’s current facilities in the Lansing area, enhancing their distribution network for radiopharmaceuticals and accelerating cancer treatment advancements. The new positions offered will start at $25 per hour, surpassing the regional median wage, and will include benefits.
The expansion is supported by the MEDC with a $750,000 performance-based grant from the Michigan Business Development Program. Kevin J. Cameron, CEO of IONETIX, praised the region, stating, “Delta Township and the Lansing region offer the ideal environment for IONETIX’s continued growth. The area’s highly skilled workforce, robust infrastructure, and strong spirit of public-private collaboration make it the perfect location for our expansion.”
This initiative is expected to not only bolster local biotech and life sciences sectors but also attract companies for clinical trials, providing patients with access to pioneering cancer treatments. Bob Trezise, President and CEO of LEAP, remarked, “This expansion is not only creating high-wage, future-forward jobs—it’s solidifying Michigan’s position as a hub for advanced biomedical research, innovation, and manufacturing.”
Additional support comes from LEAP, which has crafted a support package including funding from the Michigan New Jobs Training Program and a Michigan Works! proposal for workforce development.
Michigan stands as a beacon of innovation in the life sciences and medtech industries, offering a fertile ground for growth due to its reputable pharmaceutical and medtech companies, along with a favorable living and working environment. IONETIX’s expansion is poised to leverage Michigan’s educational and research prowess to attract and nurture talent, driving future industry innovations.
About Michigan Economic Development Corporation (MEDC)
Read More Here
